LeMaitre Vascular (NASDAQ:LMAT) Releases FY19 Earnings Guidance
LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY19 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.84-0.88 for the period, compared to the Thomson Reuters consensus estimate of $0.83. The company issued revenue guidance of $115.5-116.7 million, compared to the consensus revenue estimate of $114.09 million.LeMaitre Vascular also updated its FY 2019 guidance to $0.84-0.88 EPS.
NASDAQ:LMAT traded down $0.15 during mid-day trading on Friday, reaching $32.60. 193,077 shares of the stock were exchanged, compared to its average volume of 115,998. The company has a 50 day moving average of $28.33. The firm has a market capitalization of $644.23 million, a PE ratio of 38.81, a P/E/G ratio of 3.21 and a beta of 1.14. LeMaitre Vascular has a 1 year low of $21.79 and a 1 year high of $38.99.
LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, July 24th. The medical instruments supplier reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.02. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 16.72%. The company had revenue of $29.48 million for the quarter, compared to the consensus estimate of $28.90 million. During the same period last year, the business posted $0.43 EPS. The company’s revenue was up 9.1% on a year-over-year basis. Sell-side analysts forecast that LeMaitre Vascular will post 0.85 earnings per share for the current fiscal year.
Several brokerages have weighed in on LMAT. Barrington Research reiterated a market perform rating on shares of HealthStream in a research note on Thursday. Zacks Investment Research downgraded ExOne from a buy rating to a hold rating and set a $9.25 target price on the stock. in a research note on Saturday. First Analysis upgraded LeMaitre Vascular from a neutral rating to an outperform rating and lifted their target price for the company from $29.00 to $37.00 in a research note on Thursday. Lake Street Capital lifted their target price on LeMaitre Vascular from $27.00 to $34.00 and gave the company a hold rating in a research note on Thursday. Finally, BidaskClub downgraded Westport Fuel Systems from a buy rating to a hold rating in a research note on Friday, July 19th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. LeMaitre Vascular presently has a consensus rating of Buy and a consensus price target of $35.33.
In related news, Chairman George W. Lemaitre sold 66,037 shares of LeMaitre Vascular stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $34.45, for a total value of $2,274,974.65. Following the sale, the chairman now directly owns 3,171,124 shares in the company, valued at $109,245,221.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 19.60% of the stock is owned by insiders.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Read More: Why do analysts give a neutral rating?
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.